Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|May 16, 2022
Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of lifeRasika Korde, Rajwanth Veluswamy, Jason C Allaire, et al.
The Journal of Molecular Diagnostics : JMD|February 22, 2021
KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular TestingRajwanth Veluswamy, Philip C Mack, Jane Houldsworth, et al.
American Journal of Clinical Oncology|May 19, 2021
Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Non-Small Cell Lung CancerStephanie Tuminello, Francesca Petralia, Rajwanth Veluswamy, et al.
Transplantation|April 4, 2015
Lung Cancer Prognosis in Elderly Solid Organ Transplant RecipientsKeith Sigel, Rajwanth Veluswamy, Katherine Krauskopf, et al.
Translational Lung Cancer Research|September 21, 2020
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysisStephanie Tuminello, Daniel Sikavi, Rajwanth Veluswamy, et al.
Cancer Medicine|May 2, 2022
Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United StatesRajwanth Veluswamy, Fred R Hirsch, Emanuela Taioli, et al.
Oncotarget|January 7, 2020
Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysisStephanie Tuminello, Rajwanth Veluswamy, Wil Lieberman-Cribbin, et al.
JNCI Cancer Spectrum|May 23, 2022
Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance StatusRajwanth Veluswamy, Liangyuan Hu, Cardinale Smith, et al.
Current Problems in Cancer|June 10, 2022
Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbiditiesStacyann Bailey, Qian Wang, Chung Yin Kong, et al.
The Oncologist|April 8, 2021
Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung CancersKristin L Ayers, Tommy Mullaney, Xiang Zhou, et al.
Pageof 2